Atıf İçin Kopyala
UYSAL A., AKAD SOYER N., Ozkan M., ŞAHİN F. , VURAL F. , TÖBÜ M. , ...Daha Fazla
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.48, ss.80-83, 2018 (SCI İndekslerine Giren Dergi)
Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone.